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SUMMARY 
 
Protein Z is a vitamin K-dependent plasma protein described in its human form in 1984. The amino acid sequence 
of protein Z shows wide homology with many coagulation factors, such as VII, IX, X, and protein C. However, in 
contrast to other vitamin K-dependent coagulation factors, protein Z is not a serine protease because of the lack of 
the active centre in its amino acid sequence. The physiological function of protein Z has been uncertain for many 
years. In vitro and in vivo studies recently suggested that protein Z plays an important role in inhibiting coagu-
lation, as it serves as cofactor for the inactivation of activated factor X by forming a complex with the plasma pro-
tein Z-dependent protease inhibitor. The role of alterations of the protein Z levels has been evaluated in different 
disease states, with conflicting findings. Most of these studies were performed on ischemic vascular diseases. Re-
cently, the possible role of protein Z deficiency in the occurrence of cardiovascular diseases has been evaluated.  
(Clin. Lab. 2004;50:XXX-XXX) 
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INTRODUCTION 
 
Protein Z (PZ) is a vitamin K-dependent plasma protein 
synthesized by the liver. Bovine PZ was described for 
the first time by Prowse & Esnouf in 1977 [1]  and puri-
fication of human PZ was successfully achieved in 1984 
by Broze Jr. & Miletich [2]. It is a single-chain glyco-
protein with a molecular weight of 62 kd [3]. The com-
plete amino acid sequence of human PZ shows N-ter-
minal homology with many serine proteases, such as 
coagulation factors VII, IX, X, and protein C [4]. How-
ever, in contrast to other vitamin K-dependent coagula-
tion factors, PZ is not a serine protease because of the 
lack of the active center in its amino acid sequence [3]. 
 
The first report on a large population of healthy subjects 
showed an estimated half-life of 2-3 days and a wide 
variability of plasma levels (0.6-5.7 µg/ml), with a pro- 
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found decrease in patients on stable warfarin therapy 
[5]. In 1998, the gene encoding PZ was localized on 
chromosome 13 at band q34 where the genes of other 
vitamin K-dependent proteins have been clustered, and 
consists of 9 exons including one alternative exon. Gene 
organization is essentially similar to that of the other 
vitamin K-dependent proteins [6].  
 
Function 
Very little has been known about the physiological 
function of PZ until 1991, when Hogg & Stenflo first 
suggested a role for PZ as an enhancer of the coagula-
tion cascade [7]. Actually, they demonstrated that PZ 
was able to increase the association of thrombin with 
phospholipid vesicles in a calcium-dependent manner. 
Human PZ, however, was found to bind thrombin poor-
ly (Kd=8.9 µM) with respect to the bovine form and to 
have a minimal impact on thrombin association with 
phospholipids [8]. In fact, it has been shown that a 36 
amino acid C-terminal extension present in bovine but 
absent in human PZ is responsible for the enhanced 
binding of thrombin to bovine PZ [8]. 
 
A sharp shift occurred in 1998, when Han et al. demon-
strated that PZ circulates in a complex with another 
plasma  protein,  the  so-called protein Z-dependent pro- 
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Figure 1: Two potential pathways of forming the Protein Z – Protein Z-dependent protease inhibitor complex 
Footnote:  PZ = Protein Z; ZPI = Protein Z-dependent protease inhibitor; Xa = Activated factor X 
 
 
 
tease inhibitor (ZPI), and limits the coagulation re-
sponse acting as a co-factor for the inhibition of activat-
ed factor X (Xa) [9]. In the presence of PZ, procoagu-
lant phospholipids and calcium it produces a rapid inhi-
bition of factor Xa in a process that appears to involve 
the formation of a calcium-dependent tertiary complex 
containing factor Xa, PZ and ZPI at the phospholipid 
surface. Two potential pathways of forming this tertiary 
complex have been hypothesized (Figure 1). Whether 
PZ and ZPI circulate together or form the complex just 
on the phospholipid surface is still unknown, although 
the first hypothesis seems to predominate.  
 
ZPI is a 62-kd single chain protein, member of the ser-
pin superfamily of proteinase inhibitors. Besides factor 
Xa, ZPI also produces a significant inhibition of activat-
ed factor XI in a reaction that does not require the pre-
sence of PZ, phospholipids or calcium [10].  
 
To investigate the role of PZ alterations in vivo, Yin et 
al., performed an experimental study by disrupting the 
PZ gene in mice. PZ knock-out mice were then cross-
bred with mice homozygous for the factor V Leiden 
mutation, and the potential prothrombotic risk associat-
ed with PZ deficiency was observed [11]. As a result, 
the PZ (-/-) genotype was shown to increase the mor-
tality of Factor V Leiden homozygous mice, indicating 
a possible role as prothrombotic factor of PZ deficiency. 
 
 
Genetic control of PZ 
Since PZ has a very broad range in the normal popula-
tion it has been suggested that it may be an acute-phase 
protein. In 1999, a paper by Undar et al. demonstrated 
an inverse correlation with interleukin-6 plasma levels 
in patients with hematological malignancies, whereas 
similar results were shown with interleukin-1ß or tumor 
necrosis factor-α [12]. However, an “in vitro” study 
failed to demonstrate the influence of some inflamma-
tory cytokines on PZ biosynthesis [13]. The authors 
suggested that the regulation of PZ biosynthesis might 
be dependent on a genetic control. 
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Several polymorphisms have been recently reported in 
the PZ gene. In 2001 Rice et al screened the entire PZ 
gene identifying 14 novel polymorphisms [14]. The 
study was set up to genotype four important polymor-
phisms (intron Fg79a, promoter a-13g, exon 8 
Arg255His and intron C insertion/deletion) in relation 
to venous thrombosis. In 564 patients with deep venous 
thrombosis and in 492 age- and sex-matched controls no 
significant differences of genotype frequencies were 
found. More recently, Lichy et al. investigated the pos-
sible association between 2 common single nucleotide 
mutations in the PZ gene (intron Fg79a and promoter 
A-13g) and the risk of cerebral ischemia [15]. They 
analyzed these polymorphisms in 200 young (< 50 
years) patients with cerebral ischemia and in 199 con-
trol subjects, also investigating the potential role of the 
PZ gene polymorphisms on PZ levels in 42 control 
subjects. As a result they found a genetic control of 
plasma PZ levels and a possible protective role for the 
A allele of the intron polymorphism on the occurrence 
of cerebral ischemia.   
 
 
PZ ALTERATIONS IN CLINICAL STUDIES 
 
Over the last years PZ has been evaluated in different 
disease states, observing controversial data concerning 
the alteration of levels.  
 
PZ in bleeding tendency 
The first clinical study was performed in 1995 by Kem-
kes-Matthes & Matthes who suggested a role for PZ as 
a factor involved in hemorrhagic tendency. The authors 
reported low PZ plasma levels in 36 patients with bleed-
ing tendency, supposing that PZ deficiency might be the 
cause of the disease state [16]. By contrast, Gamba et al. 
and Ravi et al. (1998), failed to detect a relationship be-
tween low PZ levels and the bleeding disorder in two 
additional case-control studies on a total of 63 patients 
with bleeding tendency [17,18].  
 
 
PZ in ischemic stroke 
According to the identification of ZPI, clinical interest 
on alterations of the PZ levels moved to the assessment 
of its possible association with thrombotic diseases. 
Most of these studies were performed on ischemic cere-
brovascular disease, but conflicting findings have been 
reported. In 2001, Kobelt et al. investigated PZ concen-
trations in 157 young patients (median age: 40 years) 
with an episode of ischemic stroke that had occurred 
during the previous two months, observing a higher fre-
quency of high PZ concentrations associated with an in-
creased relative risk of ischemic stroke [19]. A few 
months later, Vasse et al. performed a similar case-con-
trol study in 169 young patients (<60 years) with an epi-
sode of ischemic stroke that had occurred at least three 
months before the investigation [20]. In sharp contrast 
to Kobelt et al. they found that low PZ levels were asso-
ciated with the occurrence of the disease. Furthermore, 
a group of 59 patients with deep venous thrombosis was 
analyzed but no significant differences of the PZ plasma 
levels were observed [20]. The conflicting reports have 
been a topic of subsequent correspondence without re-
solution.  
 
Recently, additional studies on the same topic have 
been conducted. In 2002 Lopaciuk et al. demonstrated 
no relationship between PZ plasma levels and ischemic 
stroke in 99 young adults (<50 years) with a previous 
episode of ischemic stroke (i.e. within the least 6 
months) [21]. Moreover, there were no significant diffe-
rences of PZ concentration according to the etiology of 
the disease. In the same year, Heeb et al. investigated 
within 4 days the PZ levels of 154 patients (mean age: 
58 years) with a first episode of ischemic stroke [22]. 
Low PZ levels were found to be significantly associated 
with ischemic stroke (OR 2.6; 95%CI 1.5-4.3) except in 
diabetic subjects and females. On this basis, low PZ 
levels have been hypothesized to be a risk factor for 
thrombosis. 
 
A further step towards the identification of PZ as a risk 
factor for thrombosis was determined by McQuillan et 
al who conducted a case-control study on 173 patients 
with a first event of ischemic stroke. PZ was measured 
during the first 7 days and 3 to 6 months after the acute 
event [23]. Plasma levels of PZ measured within 7 days 
were significantly higher in cases than in the controls 
with an odds ratio of 1.75 (95%CI 1.0-3.07). Interes-
tingly, however, this association was no longer detect-
able 3 months after the acute event. The authors conclu-
ded that elevated PZ levels were significantly associated 
with ischemic stroke, and that elevated levels during the 
acute phase could be explained by an acute-phase re-
sponse. More recently, a study conducted on Sneddon’s 
syndrome, a syndrome characterized by ischemic cere-
brovascular events with or without antiphospholipid 
antibodies (aPL), showed a higher prevalence of low PZ 
values in 26 young patients (<50 years) with an aPL-
negative subset of the disease compared to control sub-
jects [24].   
 
 
PZ in pathologic pregnancies 
Another field of interest of PZ has been the evaluation 
of its role on the pathogenesis of pathologic pregnan-
cies. In 2002, Gris et al. evaluated PZ concentrations in 
three groups of women with pathologic pregnancies of 
unexplained origin compared to a group of healthy 
mothers [25]. Two-hundred patients had unexplained 
primary recurrent miscarriage before the 8th week of 
gestation, 200 had an unexplained primary episode of 
early fetal death (10th-19th week) and 50 had an unex-
plained episode of late fetal death (>20th week). This 
study indicated a higher frequency of PZ deficiency in 
women with early fetal loss with respect to the other 
three groups,  suggesting that PZ deficiency may induce  
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Figure 2: Protein Z levels in patients with acute coronary syndromes 
Solid line = mean values of protein Z; broken line = 5th percentile of the PZ values of healthy subjects population; ACS = acute coronary syndromes 
 
 
 
an enhanced risk of severe placental insufficiency soon 
after the connection of the maternal and the fetal circu-
lation.   
 
A novel mechanism by which PZ can induce a throm-
botic complication during pregnancy has been hypo-
thesized by the same author in 2003 [26]. Actually, Gris 
et al. investigated the incidence of anti-protein Z anti-
bodies in 216 women with abnormal pregnancies, show-
ing that high levels of these antibodies were associated 
with the risk of recurrent embryo losses or fetal deaths. 
However, anti-protein Z IgG and IgM antibodies were 
not correlated with plasma PZ concentrations. Further-
more, it has recently been demonstrated that PZ defi-
ciency and positive anti-PZ antibodies were indepen-
dent risk factors for a poor outcome of treated pregnan-
cies in women with a positive thrombophilic pattern and 
a previous unexplained fetal loss [27]. 
 
 
PZ in antiphospholipid antibodies syndrome 
During the last few years it has also been suggested that 
PZ might be associated with aPL as PZ possibly acts as 
potential antigen for aPL. On this basis, Steffano et al. 
evaluated PZ plasma levels in 53 patients with persis-
tent aPL and in 36 healthy subjects [28]. They found 
low PZ levels in patients with aPL compared to the con-
trols, especially in those with a lupus anticoagulant acti-
vity, whereas no significant difference was found in 
patients with anticardiolipin antibodies in comparison to 
control subjects. This observation was confirmed by 
McColl et al. who showed low PZ plasma levels in wo-
men with aPL compared to a group of female control 
subjects and a group of women with a previous episode 
of venous thromboembolism without evidence of aPL 
[29]. The mechanism by which PZ plasma levels could 
be decreased in patients with aPL is not yet known.  
 
However, Forastiero et al. recently suggested that the 
PZ/ZPI complex is commonly impaired in aPL patients 
[30]. In this case-control study it was observed that fac-
tor Xa inactivation by PZ/ZPI was slightly delayed in 
the presence but not in the absence of B2-glycoprotein-I 
antibodies, and that concomitant PZ deficiency in sub-
jects with aPL could contribute to the development of 
the clinical features associated with the aPL syndrome. 
 
 
PZ in different clinical disease states 
PZ alterations have been also evaluated in association 
with several different clinical disorders. Increased levels 
of PZ were found in patients undergoing hemodialysis 
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procedures [31] whereas low PZ levels were found in 
patients with nephrotic syndrome [32]. The prothrom-
botic tendency associated with low levels of PZ was 
studied by Kemkes-Matthes et al. in 46 patients with 
factor V Leiden mutation and a past thromboembolic 
episode [33]. This study demonstrated that patients with 
a concomitant PZ deficiency had experienced deep vein 
thrombosis at an earlier age. PZ levels were also evalu-
ated in atrial fibrillation by Marco et al., but no signifi-
cant differences between patients and controls and ac-
cording to aspirin therapy were observed [34]. More-
over, data on the association of low PZ levels with in-
flammatory chronic diseases, such as Behçet’s disease 
and ischemic colitis have been recently reported [35, 
36]. 
 
 
PZ and acute coronary syndromes 
Recently, a possible association between PZ levels and 
arterial thrombosis has been demonstrated [37]. In this 
study the role of PZ in 223 patients with acute coronary 
syndromes (ACS) referred to the Coronary Intensive 
Therapy Unit of the University of Florence for coronary 
angiography and in 265 healthy subjects was evaluated. 
None of the patients had liver or renal dysfunction. 
None was under oral anticoagulant treatment. Prothrom-
bin time was within the normal range (> 80%) in the 
entire study population, and patients with positivity for 
antiphospholipid antibodies were excluded from the 
study. Significantly lower PZ levels in patients (1508 ± 
730 ng/mL) than in controls (1728 ± 594 ng/mL) were 
found (Figure 2). No significant differences of PZ levels 
were observed when grouping the subjects for the tradi-
tional cardiovascular risk factors (smoking habit, dysli-
pidemia, hypertension, diabetes and BMI).  
As PZ levels below the 5th percentile (565 ng/mL) of 
the normal distribution of values in the control subjects 
was considered, a higher prevalence (15.7%) of patients 
with respect to healthy subjects (4.9%) was observed. 
Moreover, logistic regression analysis performed in or-
der to investigate the possible relationship between PZ 
deficiency and the disease showed an increased risk of 
ACS with reduced PZ levels (OR=3.6; 99%CI 1.5-8.6; 
p < 0.0001). From the multivariate analysis, adjusted for 
all traditional cardiovascular risk factors and for fibrino-
gen, the increased susceptibility to disease with low lev-
els of PZ was confirmed (OR=3.3; 99%CI 1.1-9.7; p = 
0.004). Furthermore, the contemporary presence of PZ 
levels < 5th percentile and smoking habit led to an in-
creased susceptibility of ACS (OR 9.5; 99%CI 2.4-37.2; 
p < 0.0001). Also performed was a stratification of pa-
tient groups according to the different manifestations of 
disease, acute myocardial infarction and unstable angi-
na, and to the number of vessels with stenosis > 75% 
(monovessel and multivessel disease) but no difference 
was found between the PZ levels in both groups.  
 
 
 
This report was the first study investigating PZ in 
patients with ACS. It documented that in both mani-
festations of ACS the PZ plasma values were signifi-
cantly lower than in comparable controls, and that PZ 
levels lower than the 5th percentile were associated with 
ACS, at univariate (OR=3.6) and multivariate (OR=3.3) 
analysis. The observation of a higher susceptibility to 
ACS associated to the contemporary presence of smok-
ing habit and low levels of PZ may stem from the wider 
involvement of inflammatory reactions secondary to 
smoking damage. Therefore, these results add further 
weight to the possible role of PZ in the occurrence of 
arterial thrombosis and stimulate the need for further 
studies to investigate this protein in relation to the pro-
thrombotic state and in different phases of activity of 
coronary heart disease.  
 
 
CONCLUSION 
 
Protein Z is a glycoprotein with structural similarities to 
some coagulation factors. Many studies have attempted 
to determine the pathophysiological role of PZ on the 
occurrence of vascular diseases. Unfortunately, the cli-
nical significance of PZ remains  to be determined. Re-
cent researches have shown that low PZ plasma levels 
are associated with both ischemic stroke and coronary 
artery disease. The explanation for the decrease of PZ 
levels in patients suffering from this kind of diseases is 
uncertain at present. Whether low PZ levels concur with 
the hypercoagulability state documented in these pa-
tients, thus preceding the occurrence of the ischemic 
event or, on the other hand, whether they are just the ex-
pression of a consumption occurring during this patho-
logic process needs to be demonstrated by additional 
studies.  
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